Published Online:March 2026
Product Name:The IUP Journal of Case Folio
Product Type:Article
Product Code:IJCF100326
DOI:10.71329/CaseFolio/2026.26.1.131-145
Author Name:Nitin S Wani
Availability:YES
Subject/Domain:Management
Download Format:PDF
Pages:131-145
“Which option(s) should we be choosing?” Mudit Dandwate, CEO and Co-founder of the health tech startup Turtle Shell Technologies asked his CTO and co-founder, Gaurav Parchani, as they sat in their office in Bengaluru, and reviewed their financial statements. Turtle Shell Technologies had a proven innovative product—Dozee, India’s first AI-based contactless remote patient monitoring solution—backed by $30.5 mn in capital and the trust of strategic investors gained through multiple funding rounds. However, revenue growth had not yet translated into profitability. They were contemplating three major options to scale Dozee and enhance its impact. Dandwate stood at a pivotal crossroads, wrestling with the dilemma of scaling Dozee and enhancing its impact. Should he prioritize expanding within the hospital market, navigating the complex terrain of public and private healthcare systems or should he shift focus again to the consumer market, with its distinct challenges and opportunities, or embark on an ambitious international expansion in uncharted waters? This dilemma was not just a strategic choice but also a pressing matter that could define the future trajectory of Dozee. With the urgency to act swiftly in a rapidly evolving healthcare landscape and meet the expectations and earn the trust of the investors, Dandwate had to weigh the potential impact and opportunities of each path. The stakes were high, and the clock was ticking—what would be his next move?
On June 29, 2024, the Bengaluru office of Turtle Shell Technologies felt charged with tension. The clock was ticking—loudly. “Which option(s) should we be choosing?” The question came from Mudit Dandwate, the CEO and Co-founder, directed at his CTO and co-founder, Gaurav Parchani.